TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17767075

Group type: EXPERIMENTAL
Intervention: Aprotinin (10,000 KIU test dose, 2 million KIU load, 0.5 million KIU per hour)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 393
Study: 15164290

Group type: EXPERIMENTAL
Intervention: Clinical meniscus tests with high specificity and low sensitivity
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Clinical meniscus tests with high sensitivity and low specificity
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of different tests
Number of subjects: 64
Study: 12053271

Group type: EXPERIMENTAL
Intervention: Management of toxoplasma encephalitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management of primary central nervous system lymphoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management of cryptococcal meningitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management of cytomegalovirus encephalitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management of progressive multifocal leukoencephalopathy
Number of subjects: 0
Study: 9696955

Group type: EXPERIMENTAL
Intervention: Caffeine (4.5 mg. 1(‐1) and 9 mg. 1(‐1))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Theophylline (3 mg. 1(‐1), 6 mg. 1(‐1), and 12 mg. 1(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine and Theophylline (all doses)
Number of subjects: 10
Study: 7511070

Group type: EXPERIMENTAL
Intervention: Farmorubicin (FARM) at a dose of 72 mg/body
Number of subjects: 415

Group type: COMPARATOR
Intervention: Adriamycin (ADR) at a dose of 48 mg/body
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Adriamycin (ADR) in low-risk category
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Farmorubicin (FARM) in low-risk category
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Adriamycin (ADR) in high-risk category
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Farmorubicin (FARM) in high-risk category
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Change in serum alpha-fetoprotein level
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Extent of Lipiodol accumulation in the tumor
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Extent of tumor reduction
Number of subjects: 415
Study: 3947524

Group type: EXPERIMENTAL
Intervention: Nebulizer therapy with salbutamol (1 mg in 2 ml of physiological saline) driven by piped oxygen at 8 litres/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebulizer therapy with salbutamol (1 mg in 2 ml of physiological saline) driven by piped oxygen at 6 litres/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebulizer therapy with salbutamol (1 mg in 2 ml of physiological saline) driven by piped oxygen at 4 litres/min
Number of subjects: 10
Study: 29114907

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg) intravenous infusion at day 0 and at 12 months
Number of subjects: 306
Study: 27296360

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study: 24862906

Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT)
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT) in nonischemic cardiomyopathy
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT) in ischemic patients
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT) in nonischemic patients
Number of subjects: 983
Study: 22347699

Group type: EXPERIMENTAL
Intervention: Continuous counselling and medical advice in the intervention group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 20302588

Group type: EXPERIMENTAL
Intervention: 1-week quadruple therapy (tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., esomeprazole 20 mg b.i.d.)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 2-week quadruple therapy (tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., esomeprazole 20 mg b.i.d.)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 1-week quadruple therapy
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 2-week quadruple therapy
Number of subjects: 227
Study: 18380529

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 28
Study: 18506347

Group type: EXPERIMENTAL
Intervention: Continuous suture technique
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Interrupted suture technique
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the interrupted suture group)
Number of subjects: 61
Study: 15715813

Group type: EXPERIMENTAL
Intervention: Intercessory prayer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 11072058

Group type: EXPERIMENTAL
Intervention: Mindfulness of movement intervention (six individual one-to-one sessions, audio and videotape aides)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (current care)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mindfulness of movement intervention
Number of subjects: 8
Study: 9411543

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 116

Group type: COMPARATOR
Intervention: Drug-free regimen
Number of subjects: 116

Group type: COMPARATOR
Intervention: Liver necrosis index (for drug-free regimen)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 116
Study: 8416022

Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 8
Study: 3305334

Group type: EXPERIMENTAL
Intervention: Low-tar cigarette
Number of subjects: 183

Group type: COMPARATOR
Intervention: Middle-tar cigarette
Number of subjects: 183
Study: 30958831

Group type: EXPERIMENTAL
Intervention: SCBSCT‐BA (Cognitive-behavioral smoking cessation treatment with behavioral activation)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: SCBSCT (Standard cognitive-behavioral treatment)
Number of subjects: 275

Group type: COMPARATOR
Intervention: SCBSCT‐BA
Number of subjects: 275

Group type: COMPARATOR
Intervention: Both active groups (SCBSCT‐BA and SCBSCT)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Participants who quit smoking
Number of subjects: 275
Study: 30256095

Group type: EXPERIMENTAL
Intervention: Combined water treatment, sanitation, handwashing (WSH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 27325795

Group type: EXPERIMENTAL
Intervention: Vitamin D 1000 IU/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vitamin D 400 IU/day
Number of subjects: 50
Study: 25294886

Group type: EXPERIMENTAL
Intervention: FOLFOX ± cetuximab therapy
Number of subjects: 1657
Study: 22083298

Group type: EXPERIMENTAL
Intervention: CCM device activated
Number of subjects: 21

Group type: COMPARATOR
Intervention: CCM device deactivated
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CCM device activated under dobutamine stress
Number of subjects: 21

Group type: COMPARATOR
Intervention: CCM device deactivated under dobutamine stress
Number of subjects: 21
Study: 19606688

Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation of gallbladder contractility after standard fatty meal stimulation
Number of subjects: 113

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Follow-up ultrasound evaluation after successful treatment of basic diseases
Number of subjects: 113
Study: 17826777

Group type: EXPERIMENTAL
Intervention: Testosterone levels measured prior to viewing sexual stimuli
Number of subjects: 15
Study: 15118191

Group type: EXPERIMENTAL
Intervention: Glycogen depletion protocol followed by 15-min downhill run (DEP group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Glycogen depletion protocol followed by carbohydrate repletion protocol (>80% CHO) prior to downhill running (FED group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 15-min downhill running protocol only (ECC group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: All groups (DEP, FED, ECC)
Number of subjects: 33
Study: 11564001

Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9744013

Group type: EXPERIMENTAL
Intervention: Glucose 33% solution
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Glucose 5% solution
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 65
Study: 8113846

Group type: EXPERIMENTAL
Intervention: Sequential treatment: cisplatin 100 mg/m2 over 15 minutes on day 1 plus 5‐FU 1.0 g/m2 by continuous infusion on days 1 to 5, followed by 70 Gy of radiation in 7 to 8 weeks.
Number of subjects: 214

Group type: COMPARATOR
Intervention: Concomitant treatment: cisplatin 60 mg/m2 over 15 minutes on day 1 plus 5‐FU 800 mg/m2 by continuous infusion on days 1 to 5 plus radiation 2 Gy on days 1 to 5, repeated every other week for seven cycles.
Number of subjects: 214

Group type: COMPARATOR
Intervention: Concomitant treatment
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Sequential treatment
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Sequential treatment and Concomitant treatment
Number of subjects: 214
Study: 2962483

Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolysis
Number of subjects: 266

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 266
Study: 28918669

Group type: EXPERIMENTAL
Intervention: Mobile app for patient education and engagement
Number of subjects: 205

Group type: COMPARATOR
Intervention: Spiral notebook guide for patient education and engagement
Number of subjects: 205
Study: 26059709

Group type: EXPERIMENTAL
Intervention: Tap water
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0·9% sodium chloride sterile solution
Number of subjects: 120
Study: 25680887

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (CCB) group: losartan 50 mg plus amlodipine 5 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACEI) group: enalapril 5 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Thiazide diuretic (HCTZ) group: hydrochlorothiazide 12.5 mg
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control period (usual dose of ARB)
Number of subjects: 109
Study: 23966328

Group type: EXPERIMENTAL
Intervention: Low-fat milk (475 mL)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Rice milk (isocaloric volume)
Number of subjects: 19
Study: 21910712

Group type: EXPERIMENTAL
Intervention: 1450 nm laser treatment (Candela Smoothbeam laser); 3 treatments performed monthly, using a double-pass technique, 6 mm spot size, 210 ms pulse duration, fluence of 8 or 9 J cm(‐2)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control side (untreated side of the face)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 1450 nm laser treatment
Number of subjects: 38
Study: 18939389

Group type: EXPERIMENTAL
Intervention: Intensive glucose-lowering (hemoglobin A1c target < 6.0%)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Standard treatment (hemoglobin A1c target 7.0% to 7.9%)
Number of subjects: 10000
Study: 17023867

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (MPH-IR) at 2.5 mg t.i.d.
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (MPH-IR) at 5 mg t.i.d.
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (MPH-IR) at 7.5 mg t.i.d.
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Best-dose MPH
Number of subjects: 303
Study: 12055318

Group type: EXPERIMENTAL
Intervention: High protein (HP) diet
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low protein (LP) diet
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 10079408

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI) (n = 126 oocytes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard insemination techniques (group II) (n = 138 oocytes)
Number of subjects: 20
Study: 8838389

Group type: EXPERIMENTAL
Intervention: Practice on a lateralized mental rotation task
Number of subjects: 92
Study: 2359578

Group type: EXPERIMENTAL
Intervention: Monitored uterine activity
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Symptoms
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Uterine activity
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cervical examination at a routine office visit
Number of subjects: 51
Study: 7307036

Group type: EXPERIMENTAL
Intervention: Miconazole tampons (2 tampons daily for 5 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Clotrimazole vaginal tablets (1 tablet daily for 6 days)
Number of subjects: 51
Study: 30902692

Group type: EXPERIMENTAL
Intervention: Fungal keratitis treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bacterial keratitis treatment
Number of subjects: 100
Study: 28351060

Group type: EXPERIMENTAL
Intervention: CPAP withdrawal
Number of subjects: 183
Study: 26418530

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) for 30 days
Number of subjects: 2876

Group type: COMPARATOR
Intervention: No IPC (routine care)
Number of subjects: 2876

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 2876
Study: 22407182

Group type: EXPERIMENTAL
Intervention: BPTB graft
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: DLSG graft
Number of subjects: 114
Study: 21242676

Group type: EXPERIMENTAL
Intervention: Acetate-free hemodiafiltration (AF HFR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetate hemodiafiltration (HFR with acetate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard bicarbonate dialysis (BHD)
Number of subjects: 30
Study: 18945306

Group type: EXPERIMENTAL
Intervention: PUVA + IFN-alpha
Number of subjects: 29

Group type: COMPARATOR
Intervention: PUVA
Number of subjects: 29
Study: 17669915

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 0
Study: 15182379

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided by community pharmacists after training
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual dispensing services provided by community pharmacists before training
Number of subjects: 700
Study: 11510929

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9400878

Group type: EXPERIMENTAL
Intervention: Consultation-liaison psychiatry service (C-L) referrals without symptom-matched controls (n = 27)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Symptom-matched C-L referrals
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non-referred controls (matched on demographic characteristics)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non-referred controls (matched on initial symptomatology)
Number of subjects: 86
Study: 8287317

Group type: EXPERIMENTAL
Intervention: Psoas training (TG)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Deltoid training (CG)
Number of subjects: 78
Study: 3815287

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31307209

Group type: EXPERIMENTAL
Intervention: Aligners (AL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fixed Appliances (FA)
Number of subjects: 100
Study: 31549959

Group type: EXPERIMENTAL
Intervention: Locked retrograde nail fixation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Anatomical distal femoral locking plate fixation
Number of subjects: 23
Study: 28928192

Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl trinitrate (GTN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard practice (placebo)
Number of subjects: 0
Study: 25079365

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1ra)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 22777396

Group type: EXPERIMENTAL
Intervention: Emotional demands (unmet care needs)
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: Emotional demands (client health and emotional suppression)
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: Emotional demands (unfair treatment, client's family abuse)
Number of subjects: 1599
Study: 21710402

Group type: EXPERIMENTAL
Intervention: yohimbine (0.4 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: social stress test (SST)
Number of subjects: 24
Study: 19401341

Group type: EXPERIMENTAL
Intervention: Dual-chamber ICDs
Number of subjects: 334

Group type: COMPARATOR
Intervention: Single-chamber ICDs
Number of subjects: 334
Study: 16846398

Group type: EXPERIMENTAL
Intervention: Metformin-glibenclamide combination tablets (Glucovance)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 50
Study: 15144688

Group type: EXPERIMENTAL
Intervention: Alendronate sodium
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 10702428

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma sequestration (pheresis)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 9402455

Group type: EXPERIMENTAL
Intervention: Low-energy intracardiac cardioversion (1 to 15 J)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Transthoracic external cardioversion (360 J)
Number of subjects: 187
Study: 8401150

Group type: EXPERIMENTAL
Intervention: Cold water immersion at 18 degrees, 22 degrees, or 26 degrees C for 120 min.
Number of subjects: 21
Study: 3005138

Group type: EXPERIMENTAL
Intervention: Pectin (12 g/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cellulose (15 g/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lignin (12 g/day)
Number of subjects: 30
Study: 2851443

Group type: EXPERIMENTAL
Intervention: CEP/MEC chemotherapy (cyclophosphamide 500 mg/m2 i.v. day 1; epirubicin 50 mg/m2 i.v. day 1; cisplatin 80 mg/m2 i.v. day 1; alternated with methotrexate 30 mg/m2 i.v. day 1; etoposide 200 mg/m2 i.v. day 1; CCNU 70 mg/m2 per os, day 1) until progression.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Supportive care (Arm B).
Number of subjects: 92
Study: 31221047

Group type: EXPERIMENTAL
Intervention: Automated symptom management (ASM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comprehensive symptom management (CSM)
Number of subjects: 0
Study: 30921804

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with house dust mite extract
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (non-allergic individuals)
Number of subjects: 6
Study: 28673214

Group type: EXPERIMENTAL
Intervention: TAP catheter (18 ml 0.5% ropivacaine every four hours)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: PRS catheter (18 ml 0.5% ropivacaine every four hours)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: SC catheter (18 ml 0.5% ropivacaine every four hours)
Number of subjects: 94
Study: 25945018

Group type: EXPERIMENTAL
Intervention: rabeprazole plus irsogladine maleate (IM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: rabeprazole plus placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: rabeprazole plus irsogladine maleate (IM) in patients with NERD grade N
Number of subjects: 100
Study: 23725944

Group type: EXPERIMENTAL
Intervention: BT + MT
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: BT + VRS
Number of subjects: 64

Group type: COMPARATOR
Intervention: box-free
Number of subjects: 64

Group type: COMPARATOR
Intervention: BT
Number of subjects: 64
Study: 21255767

Group type: EXPERIMENTAL
Intervention: 10‐week web‐based unguided self‐help treatment for social phobia
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 10‐week web‐based self‐help treatment with minimal weekly therapist support via email
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 10‐week web‐based self‐help treatment with flexibly stepped-up support (email or telephone contact on demand)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 81
Study: 19298412

Group type: EXPERIMENTAL
Intervention: prulifloxacin 600 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 72
Study: 16504691

Group type: EXPERIMENTAL
Intervention: Exercise intervention (PT) - tailored exercises under physiotherapist supervision for 15 to 30 minutes every second hospital day
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard care (CT) - control group
Number of subjects: 69
Study: 12765806

Group type: EXPERIMENTAL
Intervention: Dalteparin (2,500 units once a day, SC, for 7 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin (5000 units every 12 hours, SC, for 7 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 100
Study: 10983362

Group type: EXPERIMENTAL
Intervention: Amitriptyline (12.5-25 mg/daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10-20 mg/daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Maprotiline (10-25 mg/daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 60
Study: 9313603

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 310

Group type: COMPARATOR
Intervention: Mibefradil 6.25 mg, 12.5 mg, 25 mg, 50 mg, 100 mg
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 8383396

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment based on ambulatory monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antihypertensive treatment based on conventional sphygmomanometry
Number of subjects: 0